Sector Expert: Greg Wade

Wedbush

Greg Wade, managing director and senior analyst with Wedbush Securities, has worked on the sellside since early 2000, first at Pacific Growth Equities and subsequently at Wedbush PacGrow LifeSciences, where he was promoted to managing director in 2011. Wade's coverage of emerging biopharmaceutical companies is supported by analyst team members David Nierengarten and Chris Marai. Wade earned an undergraduate degree with honors in medical biophysics and a doctorate in physiology from the University of Western Ontario in London, Canada.



Recent Quotes

"There are quite a few catalysts in H2/13 for ONCY."

The Life Sciences Report Interview with Greg Wade (8/8/13)
more >

"We reiterate our Outperform rating on ONCY."

— Greg Wade, Wedbush (8/1/13)
more >

"Expect ONCY's stock to move sharply after positive data from cancer studies."

— Greg Wade, Wedbush (3/19/13)
more >

"We reiterate our Outperform rating on OGXI."

— Greg Wade, Wedbush (3/11/13)
more >

"We continue to be encouraged by the potential for ONCY's drug and are very eager to see how this phase 3 study turns out."

The Life Sciences Report Interview with Greg Wade (2/7/13)
more >

"We are maintaining our Outperform rating for OGXI."

— Greg Wade, Wedbush (12/19/12)
more >

"We reiterate our Outperform rating for ONC."

— Greg Wade, Wedbush (12/13/12)
more >

"We are maintaining our Outperform rating on OGXI."

— Greg Wade, Wedbush (11/9/12)
more >



Due to permission requirements, not all quotes are shown.